|
Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). |
|
|
Honoraria - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Speakers' Bureau - Celgene; Janssen |
Research Funding - Bayer; Celgene; Janssen; Novartis |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer; Bristol-Myers Squibb; Hutchison MediPharma; Novartis; Pfizer; Pharmacyclics |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Gilead Sciences; Janssen; Mundipharma; Roche/Genentech; SERVIER |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Novartis; NOvimmune; Roche/Genentech |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |